This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:cancer [04.20.2019] – [Evidence of infectious cause] sallieq | home:diseases:cancer [05.16.2019] – [Recent research] sallieq | ||
---|---|---|---|
Line 24: | Line 24: | ||
* **lung cancer** – According to a 2011 meta-analysis, | * **lung cancer** – According to a 2011 meta-analysis, | ||
* **prostate cancer** – In a 2005 culture-based study, Cohen found that // | * **prostate cancer** – In a 2005 culture-based study, Cohen found that // | ||
- | * **Table of cancers** with associated | + | * **Table of cancers** with associated |
Line 88: | Line 88: | ||
Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. (({{pubmed> | Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. (({{pubmed> | ||
+ | |||
+ | 2014 a Cochrane meta-analysis that included 18 randomized clinical trials comparing vitamin D administration versus no intervention in healthy population found no difference regarding cancer incidence. | ||
====1, | ====1, | ||
Line 378: | Line 380: | ||
Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer. (({{pubmed> | Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer. (({{pubmed> | ||
+ | |||
+ | This compound has antiproliferative and antimigratory effects in squamous cell carcinoma, glioblastoma, | ||
Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. So ARBs and NF-kappaB pathway inhibitors could be considered as anticancer drugs in future. | Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. So ARBs and NF-kappaB pathway inhibitors could be considered as anticancer drugs in future. |